De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Metastatic NSCLC Clinical Trial

— DIAL  

Official title:

A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05255302
• Other study ID #: IFCT-2103
• Secondary ID: 2021-006044-27
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: May 2, 2022
• Est. completion date: June 1, 2029

Study information

• Verified date: September 2023
• Source: Intergroupe Francophone de Cancerologie Thoracique
• Contact: Clinical Operations Manager
• Phone: 0156811046
• Email: contact[@]ifct.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials. The aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months (27-weeks), in patients with controlled disease.

Description:

This is a phase II-III randomized, open-labelled, multicentre study for NSCLC patients who are naive of treatment for advanced disease. Patients will be given first-line chemotherapy + pembrolizumab: platinum doublet for at least 3 cycles, either paclitaxel-carboplatin for patient with SCC or 3 cycles of pemetrexed-platinum salt followed by 2 cycles of pemetrexed and 6 cycles of pembrolizumab. Only patients with disease control, confirmed at 6 months (27-weeks) without drug-related toxicity imposing treatment discontinuation will be randomized 1:1 either to continuation of pembrolizumab (± pemetrexed for non-SCC) until disease progression or unacceptable toxicity or 2 years, or observation (± pemetrexed for non-SCC). Patients will be stratified by performance status (0 versus 1), histology (SCC versus non-SCC), PD-L1 (PD-L1 < 1% versus 49%≥PD-L1 ≥ 1% versus PD-L1>49%), sex and response at randomization (partial response versus stabilisation).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1360
• Est. completion date: June 1, 2029
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. Signed Written Informed Consent:

• Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.
• Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.

2. Patients with histologically confirmed metastatic NSCLC (Stage IV accordingly to 8th classification TNM, UICC 2015). A cytologically-proven NSCLC is allowed if a cytoblock has been prepared.

3. PD-L1 tumor content as assessed locally by the investigator center.

4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.

5. Weight loss< 10% within 3 months of study entry.

6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease.

7. Age= 18 years, <75 years

8. Life expectancy > 3 months

9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria

10. The Investigator must confirm prior to enrolment that the patient has adequate tumor tissue available. Tumor biopsy should be exploitable for molecular analysis. If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with IFCT. Note: Tumor tissue collected after the patient was diagnosed with metastatic disease is preferred. Tumor tissue sample must not be from locations previously radiated. Tumor sample must be 1 block or at least 7 unstained slides of analyzable tissue.

11. Adequate biological functions:

Creatinine Clearance = 45 mL/min (Cockcroft or MDRD or CKD-epi); neutrophils= 1500/mm3 ; platelets =100 000/mm3 ; Hemoglobin= 9g/dL ; AST and ALT< 3x ULN, total bilirubin < 2xULN (patients with hepatic metastases or Gilbert's syndrome must have AST and ALT = 5 x ULN and a baseline total bilirubin = 2xULN).

12. Women of childbearing potential (WOCBP) and sexually active should use an efficacious contraception method within the 28 days preceding the first dose and during the 6 months following the last dose of treatment. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) prior to the start of study drug.

13. For Male subjects who are sexually active with WOCBP, an efficacious contraception method should be used during the treatment and during the 6 months following the last dose.

14. Patient has national health insurance coverage.

Exclusion Criteria:

1. Small cell lung cancer or tumors with mixed histology including a SCLC component. Note : Sarcomatoid histology is allowed. Neuro-endocrine large cell lung cancer with molecular features of small-cell lung cancer (i.e; Rb loss associated with TP53 mutation) will not be eligible. Other neuro-endocrine large cell subtypes, i.e. with adenocarcinoma features (STK11 or K-Ras mutations) will be eligible. In case of doubt, please contact the sponsor.

2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A/S mutation in exon 18, exon 20 insertion) or HER2 exon 20 insertion (either tissue or plasma cfDNA mutation).

3. Known ALK, ROS1, Ret, NTRK, NRG1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS (ADN or ARN) sequencing by local genetics and/or pathology laboratory.

4. Previous or active cancer within the previous 3 years (except for treated carcinoma in situ of the cervix, or basal cell skin cancer treated or not). Patients with a prostate adenocarcinoma history within the previous 3 years could be included in case of localized prostate cancer, with good prognostic factors according to d'Amico classification (=T2a, score de Gleason = 6 and PSA = 10 (ng/ml)) provided they were treated in a curative way (surgery or radiotherapy, without any chemotherapy).

5. Superior vena cava syndrome persisting despite VCS stenting.

6. Radiotherapy needed at initiation of tumour treatment, except bone palliative radiotherapy on a painful or compressive metastasis, respecting 1 week delay between the end of radiotherapy and the beginning of treatment

7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or stereotactic ablative brain radiotherapy or without surgical resection). At least 2 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment should be respected. Asymptomatic brain metastasis, not needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol infusions, are allowed.

8. History of previous primary immunodeficiency, organ transplantation needing an immunosuppressive treatment, any immunosuppressive drug within 28 days before randomization date, or history of severe toxicity (grade 3/4) by immune mechanism linked to another immunotherapy treatment.

9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.

10. History of active autoimmune disease including but not limited to rheumatoid polyarthritis, myasthenia, autoimmune hepatitis, systemic Lupus, Wegener's granulomatosis, vascular thrombosis associated with antiphospholipid syndrome, Sjogren's syndrome with interstitial pulmonary disease, recent Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with type I diabetes, or hypothyroidism, or immune cutaneous disease (vitiligo, psoriasis, alopecia) or benign rheumatoid polyarthritis not needing any immunosuppressive systemic treatment, or benign sicca syndrome (Sjogren) without interstitial pulmonary disease, or history of past Guillain-Barre syndrome, totally reversible with no sequelae, no systemic immunosuppressive treatment during the last 20 years, are allowed to be included.

11. Active inflammatory intestinal disease (Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea.

12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B and C according to serological tests. Patients with serological sequelae of cured viral hepatitis are allowed to be included. Past primary pulmonary tuberculosis in youth does not consist of a contra-indication. Past tuberculosis disease history does not consist of a contra-indication provided the patient was treated during at least 6 months by anti-tuberculosis antibiotic treatment.

13. Known HIV infection

14. Living attenuated vaccine received within the 30 previous days

15. Previous treatment with anti-PD-1, anti-PD-L1, Anti-CTLA4 or any ICI antibody

16. Previous treatment with chemotherapy for lung cancer. However, if a patient has a lung adenocarcinoma, previous cisplatin treatment for another cancer type with squamous histology (Head and Neck, bladder) may be allowed provided the sponsor accepts, and provided blood tests are normal (see above).

17. General serious condition such as congestive uncontrolled cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction within the previous 6 months), history or stroke within the 6 previous months. Patients with a significant cardiac history, even if controlled, should have a LVEF > 50%.

18. Pre-existing moderate or severe lung interstitial disease as assessed by the diagnosis CT-scan.

19. Inability to comply with study and/or follow-up procedures for family, social, geographic or psychological reasons.

20. Pregnant, lactating, or breastfeeding women.

21. Patients deprived of liberty by judicial or administrative decision

22. Patient who is subject to legal protection or who is unable to express his will

Related Conditions & MeSH terms

• Metastatic NSCLC

Intervention

Drug:
• Pembrolizumab before randomization
Pembrolizumab 200 mg every 3 weeks before randomization
• Chemotherapy
Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
• Pemetrexed
Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
• Pembrolizumab after randomization
Pembrolizumab 200 mg every 3 weeks after randomization

Locations

Country	Name	City	State
France	Aix-en-Provence - CH	Aix-en-Provence
France	Amiens - Clinique de l'Europe	Amiens
France	Angers - CHU	Angers
France	Avignon - CH	Avignon
France	Besançon - CHU	Besançon
France	Bordeaux - Polyclinique	Bordeaux
France	CHU de Bordeaux	Bordeaux
France	Caen - CHU Côte de Nacre	Caen
France	Cannes - CH	Cannes
France	Chauny - Centre Hospitalier	Chauny
France	CH	Colmar
France	Centre Georges François Leclerc	Dijon
France	CHRU Grenoble	Grenoble
France	La Roche Sur Yon - CH	La Roche Sur Yon
France	CH de Versailles	Le Chesnay
France	Centre Hospitalier - Pneumologie	Le Mans
France	CHRU de Lille	Lille
France	CHU de Limoges	Limoges
France	Lyon - Hôpital Jean Mermoz	Lyon
France	Marseille - Hôpital Européen	Marseille
France	Meaux - CH	Meaux
France	Metz - Hôpital Robert Schuman	Metz
France	Hôpital Arnaud de Villeneuve	Montpellier
France	Centre Hospitalier	Mulhouse
France	Nantes - CHU Hôpital Laënnec	Nantes
France	Nice - CRLCC	Nice
France	Orléans - CHR	Orléans
France	Hôpital Bichat - Claude - Bernard	Paris
France	Institut CURIE	Paris
France	Paris - APHP - Hopital Tenon	Paris
France	Reims - CHU	Reims
France	Rouen - CHU	Rouen
France	Centre René Huguenin	Saint-Cloud
France	CHU Saint-Etienne Pneumologie	Saint-Etienne
France	Hôpital privé de la Loire	Saint-Étienne
France	Institut de Cancérologie de l'Ouest - René Gauducheau	Saint-Herblain
France	Saint-Nazaire - Clinique Mutualiste de l'Estuaire	Saint-Nazaire
France	CHU de La Réunion-Site Sud	Saint-Pierre
France	Centre Hospitalier	Saint-Quentin
France	Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg	Strasbourg
France	Centre Hospitalier Intercommunal	Toulon
France	Hôpital Larrey (CHU)	Toulouse
France	CHRU de Tours	Tours
France	Centre Alexis Vautrin	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Intergroupe Francophone de Cancerologie Thoracique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase II: 18-month overall survival (OS)	Rate of patients not dead 18 months after inclusion	18 months after inclusion
Primary	Phase III: overall survival	Time from date of inclusion to the date of death due to any cause	about 24 months after randomization
Secondary	Incidence, nature, and severity of adverse events	Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)	about 24 months after randomization
Secondary	Time until definitive health related quality of life score deterioration	The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30/LC13 questionnaire will be used to determine time until definitive HRQoL score deterioration.	about 24 months after randomization
Secondary	Change from baseline of EuroQol Quality of Life 5-Dimension 5-Level Scale	Change from baseline of EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) at all scheduled time points.	about 24 months after randomization
Secondary	Progression-Free Survival (PFS)	Time between the date of randomization and the first date of documented progression, as determined by investigator, or death due to any cause, whichever occurs first.	about 24 months after randomization
Secondary	OS according to histological subtype	Time from date of inclusion to the date of death due to any cause according to histological subtype.	about 24 months after randomization
Secondary	PFS according to histological subtype	Time between the date of randomization and the first date of documented progression, as determined by investigator, or death due to any cause, whichever occurs first according to histological subtype.	about 24 months after randomization
Secondary	OS according to PDL1 tumor level	Time from date of inclusion to the date of death due to any cause according to PDL1 tumor level.	about 24 months after randomization
Secondary	PFS according to PDL1 tumor level	Time between the date of randomization and the first date of documented progression, as determined by investigator, or death due to any cause, whichever occurs first according to PDL1 tumor level.	about 24 months after randomization

External Links

•   IFCT website